Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation.
Farina L, Barretta F, Scarfò L, Bruno B, Patriarca F, Frustaci AM, Coscia M, Salvetti C, Quaresmini G, Fanin R, Onida F, Magagnoli M, Zallio F, Vallisa D, Reda G, Ferrario A, Corradini P, Montillo M. Farina L, et al. Among authors: frustaci am. Biol Blood Marrow Transplant. 2020 Oct;26(10):e256-e262. doi: 10.1016/j.bbmt.2020.06.032. Epub 2020 Jul 9. Biol Blood Marrow Transplant. 2020. PMID: 32653626 Free article.
Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.
Montillo M, Tedeschi A, Gaidano G, Coscia M, Petrizzi VB, Orlandi E, Cascavilla N, Ghia P, Motta M, Gallamini A, Frustaci AM, Rossi D, De Paoli L, Nichelatti M, Morra E, Massaia M. Montillo M, et al. Among authors: frustaci am. Haematologica. 2014 Sep;99(9):e159-61. doi: 10.3324/haematol.2014.106740. Epub 2014 Jun 27. Haematologica. 2014. PMID: 24972768 Free PMC article. No abstract available.
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients.
Tedeschi A, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortelezzi A, Nador G, Scarfò L, Cairoli R, Frustaci AM, Dalceggio D, Picardi P, De Paoli L, Orlandi E, Rambaldi A, Massaia M, Gaidano G, Montillo M; Rete Ematologica Lombarda–CLL Workgroup. Tedeschi A, et al. Among authors: frustaci am. Haematologica. 2015 Dec;100(12):e501-4. doi: 10.3324/haematol.2015.132035. Epub 2015 Aug 20. Haematologica. 2015. PMID: 26294723 Free PMC article. Clinical Trial. No abstract available.
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
Mauro FR, Galieni P, Tedeschi A, Laurenti L, Del Poeta G, Reda G, Motta M, Gozzetti A, Murru R, Caputo MD, Campanelli M, Frustaci AM, Innocenti I, Raponi S, Guarini A, Morabito F, Foà R, Gentile M. Mauro FR, et al. Among authors: frustaci am. Am J Hematol. 2017 Jun;92(6):529-535. doi: 10.1002/ajh.24714. Epub 2017 Apr 18. Am J Hematol. 2017. PMID: 28295527 Free article.
Is HBV prophylaxis required during CLL treatment with ibrutinib?
Tedeschi A, Frustaci AM, Mazzucchelli M, Cairoli R, Montillo M. Tedeschi A, et al. Among authors: frustaci am. Leuk Lymphoma. 2017 Dec;58(12):2966-2968. doi: 10.1080/10428194.2017.1317094. Epub 2017 May 23. Leuk Lymphoma. 2017. PMID: 28535112 No abstract available.
71 results